Precede Biosciences has announced new data from the AACR Special Conference in Cancer Research: Liquid Biopsy (LBx) 2024, showcasing the potential of its novel epigenomic liquid biopsy platform to predict response to Lutetium-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study suggests that a simple blood test could provide a real-time, non-invasive assessment of PSMA expression, potentially guiding treatment decisions and improving patient outcomes.
Non-Invasive PSMA Expression Readout
The research indicates that the liquid biopsy platform can accurately quantify tumor PSMA expression, a critical factor in determining the suitability of Lutetium-PSMA therapy. Jacob E. Berchuck, MD, Assistant Professor at Winship Cancer Institute of Emory University, noted that Lutetium-PSMA is an important FDA-approved treatment option for the estimated 120,000 men in the USA living with advanced mCRPC, but requires a PSMA-PET scan to confirm tumor PSMA expression. The study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response, which is an important finding given that PSMA-PET is not equally accessible across the USA and across the globe.
Broader Implications for PSMA-Targeting Therapies
Beyond Lutetium-PSMA, the findings have implications for the more than 30 PSMA-targeting medicines currently in clinical development. Rehan Verjee, Co-founder and CEO of Precede Bio, emphasized the platform's capability to resolve target expression from a simple blood draw, underscoring its potential role in enabling the success of these emerging medicines. This capability could streamline drug development and improve patient selection for clinical trials.
Addressing Unmet Needs in Prostate Cancer
Metastatic castration-resistant prostate cancer represents a significant challenge in oncology, with limited treatment options available for patients who have progressed on hormone therapy. The ability to accurately assess PSMA expression non-invasively could help to optimize treatment strategies and improve outcomes for these patients. The platform offers a potential solution to the challenges associated with PSMA-PET scans, which may not be readily available in all settings.
